Aarhus University
At AACR, the company highlighted new prospective and retrospective data that it believes helps set its platform apart from other available ctDNA technologies.
The company is positioning the blood-based test as an alternative to invasive chorionic villus sampling, the current standard in Denmark.
Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.
FIT Could Help Diagnose 'Non-Alarm' Colorectal Cancer Patients in GP Setting
The researchers argued that fecal immunochemical test could be used as "rule-in" test for patients with ambiguous symptoms.
The researchers found that tumors expressing STAG2 as a biomarker are twice as likely to recur and progress toward muscle invasion and metastasis.